Literature DB >> 31462538

Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol.

Nevio Cimolai1,2.   

Abstract

Timolol is a commonly-used topical antiglaucoma medication and has proven to be highly efficacious for most recipients. Among the reported adverse events, the neuropsychiatric spectrum has been cited, albeit for a small proportion of those treated. This review summarizes the cumulative published experience of such side effects and assesses the quality of evidence. As for other beta-blockers, whether orally or topically administered, various central nervous systems dysfunctions have been detailed in either case reports or larger patient series. The adverse event commonly resolves following drug termination. Rigorous and more definitive studies of causation are lacking, and to some, such paucity has reduced the belief of a cause and effect relationship. Until otherwise proven, deference should be afforded to the potential for topical timolol to cause neuropsychiatric side effects, and at-risk patients should be closely monitored when they are prescribed this pharmacological agent.
© 2019 Marshfield Clinic.

Entities:  

Keywords:  Adverse event; Glaucoma; Safety; Timolol; Topical agent

Mesh:

Substances:

Year:  2019        PMID: 31462538      PMCID: PMC6886891          DOI: 10.3121/cmr.2019.1486

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  58 in total

Review 1.  Pharmacogenetics of beta-blockers.

Authors:  Jaekyu Shin; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2007-06       Impact factor: 4.705

2.  From timolol to betaxolol.

Authors:  J de Vries; S A van de Merwe; L Jan de Heer
Journal:  Arch Ophthalmol       Date:  1989-05

3.  Potential systemic and ocular side effects associated with topical administration of timolol maleate.

Authors:  A B Trawick
Journal:  J Am Optom Assoc       Date:  1985-02

4.  Pharmacokinetics of oral timolol studied by mass fragmentography.

Authors:  J B Fourtillan; P Courtois; M A Lefebvre; J Girault
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

5.  Depression in patients with glaucoma as measured by self-report surveys.

Authors:  M Roy Wilson; Anne L Coleman; Fei Yu; Irene Fong Sasaki; Eric G Bing; Matthew H Kim
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

6.  Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker.

Authors:  J H Shore; F T Fraunfelder; S M Meyer
Journal:  J Clin Psychopharmacol       Date:  1987-08       Impact factor: 3.153

7.  Transient ischemic attacks and amaurosis fugax from timolol.

Authors:  J R Coppeto
Journal:  Ann Ophthalmol       Date:  1985-01

8.  Improving the therapeutic index of topically applied ocular drugs.

Authors:  T J Zimmerman; K S Kooner; A S Kandarakis; L P Ziegler
Journal:  Arch Ophthalmol       Date:  1984-04

9.  Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).

Authors:  Janet B Serle; L Jay Katz; Eugene McLaurin; Theresa Heah; Nancy Ramirez-Davis; Dale W Usner; Gary D Novack; Casey C Kopczynski
Journal:  Am J Ophthalmol       Date:  2017-12-01       Impact factor: 5.258

10.  Clinical experience with timolol maleate monotherapy of hypertension.

Authors:  J A Bannon; K A Stewart; O DeLisser; J J Schrogie
Journal:  Arch Intern Med       Date:  1986-04
View more
  1 in total

1.  Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.

Authors:  Tamara Kralj; Antonio Kokot; Mirna Zlatar; Sanja Masnec; Katarina Kasnik Kovac; Marija Milkovic Perisa; Lovorka Batelja Vuletic; Ana Giljanovic; Sanja Strbe; Suncana Sikiric; Slaven Balog; Bojan Sontacchi; Dijana Sontacchi; Matko Buljan; Eva Lovric; Alenka Boban Blagaic; Anita Skrtic; Sven Seiwerth; Predrag Sikiric
Journal:  Biomedicines       Date:  2021-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.